摘要
目的:测定Graves’病患者131I治疗前后血清FT3、FT4、sTSH、TRAb、TGA、TMA含量,探讨变化规律及在诊断、治疗中的临床意义。方法:应用标记免疫分析法测定172例Graves’病患者131I治疗前、治疗后3、6、12和18个月及43例正常人血清FT3、FT4、sTSH、TRAb、TGA、TMA的含量。结果:与治疗前及正常人比较,治疗后3个月血清FT3、FT4含量明显降低,sTSH、TRAb含量明显升高。TGA、TMA值呈上升趋势。6个月FT3、FT4、sTSH含量接近对照组,TRAb呈下降趋势,TGA、TMA值明显升高。12个月TRAb、TGA、TMA值明显下降,18个月各项指标均接近正常。结论:动态观察Graves’病患者131I治疗前后FT3、FT4、sTSH、TRAb、TGA、TMA血清中含量的变化,对观察治疗疗效、指导治疗及预后均有重要意义。
To study the clinical significances of serum FT3, FT4, sTSH, TRAb, TGA and TMA concentration changes in Graves＇ patients before and after ^131Ⅰ treatment. Methods The serum FT3, FT4, sTSH, TRAb, TGA and TMA concentrations before treatment, 3, 6, 12 and 18 months after therapy in 172 Graves＇ patients and 43 normal controls were obtained by time-resolved fluoroimmunoassay technique. Results FT3 and FT4 concentrations showed an obvious decrease 3 months after treatment, while sTSH and TRAb had remarkable high values, as TGA and TMA demonstrated a trend to increase. FT3, FT4 and sTSH concentrations were close to control group 6 months after treatment, TRAb had a decline trend. All the six indexes approached to normal 18 months after treatment. Conclusion It is of great of significance for the Graves＇ patients to accept the developmental observation of serum FT3 , FT4 , and sTSH, TRAb, TGA and TMA concentrations before and after ^131Ⅰ therapy, which provides a great of positive information for therapy guiding, observation and prognosis.
出处
《吉林大学学报（医学版）》
CAS
CSCD
北大核心
2006年第5期920-922,共3页
Journal of Jilin University：Medicine Edition
基金
吉林省科技厅基金资助课题(20030427-01)
